The Smoking Cessation treatment market offers tremendous opportunities to pharmaceutical players since there are only a few approved non-nicotinic therapies available commercially. The report covers the Smoking Cessation market trends covering key pharmaceutical companies in the market, upcoming as well as Smoking Cessation marketed therapies, unmet needs, prevailing constraints and the factors driving the market size growth.
Key takeaways from the Smoking Cessation Market Research Report
- According to DelveInsight, the Smoking Cessation market in 7MM is expected to witness a major change in the study period 2019-2032.
- The Smoking Cessation epidemiology covered in the report provides historical as well as forecasted Smoking Cessation epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- Smoking Cessation market companies are working such as Pfizer, GlaxoSmithKline, Axsome Therapeutics, Achieve Life Sciences, among several others are developing therapies for the treatment of Smoking Cessation.
- Smoking Cessation pipeline therapies such as varenicline tartrate, bupropion hydrochloride, EVT 302, Supplement: Probiotic L008-1, Sham Treatment, Acetium Lozenge, and others.
For further information on the Smoking Cessation market impact by therapies, download the Smoking Cessation sample @ Smoking Cessation Market Size
Smoking Cessation Overview
Tobacco use, primarily cigarette smoking, is the leading cause of preventable disease and death in the United States. It is well established that smoking increases the risk of different forms of cancer, including lung, liver, and colorectal. Eighty-five percent of lung cancers occur in smokers. Also, smoking increases the risk of respiratory diseases (such as chronic obstructive pulmonary disease) and cardiovascular disease. During pregnancy, smoking increases the rate of complications, including miscarriage, stillbirth, preterm birth, fetal growth restriction, and congenital anomalies. Neonatal and pediatric complications of exposure to cigarette smoking include sudden infant death syndrome and abnormal lung function in children, such as asthma
Smoking Cessation Epidemiology Segmentation in the 7MM
As per DelveInsight estimates, the total diagnosed Smoking Cessation prevalent population in the 7MM was estimated to be 49,301,950 in 2017, which rose to 50,426,314 in 2020. Out of all the 7MM, the United States was observed to occupy the highest diagnosed prevalent patient pool of Smoking Cessation. Further, the Smoking Cessation epidemiological analysis demonstrated men as the larger constituent of the patient pool as compared to women.
Keen to learn how Smoking Cessation Epidemiological Trends are going to appear in 2032 for the 7MM, Download @ Smoking Cessation Epidemiological Insights
Smoking Cessation Treatment Market Outlook
Nicotine withdrawal symptoms tend to be most intense in the first 2–3 days of quitting tobacco and gradually subsides within 2–4 weeks. The Smoking Cessation market offers effective drugs and treatments including both behavioral therapies and medications. There exists 89 distinct products and services available for management of Smoking Cessation, along with 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies such as nicotine replacement therapy (NRT) in several different forms like transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline (Chantix/Champix) are now commercially available in the Smoking Cessation therapy market. Talking about Japanese Smoking Cessation market, varenicline, NRT and some off-label therapies are available, whereas Bupropion-SR is not licensed in the market. However, the patent of Varenicline is going to expire in this year – 2021 in the EU and in 2022 in Japan.
Smoking Cessation Market Landscape
Key companies worldwide are exploring novel mechanisms to battle nicotine addiction and withdrawal symptoms. Over the decades, considerable success has been achieved in the developing standard and efficient therapies for the same. Key players, such as Pfizer, GlaxoSmithKline, Axsome Therapeutics, Achieve Life Sciences, and others are developing therapies and strengthening the Smoking Cessation market landscape. Conclusively, emerging drugs with novel mechanisms of action are going to exponentially push the Smoking Cessation market size forward. Several large-scale collaborative studies have significantly proffered novel insights into the condition and its pathophysiology. Further, there is an increasing trend observed of quitting smoking owing to better awareness of the harmful effects of tobacco-smoking as well as several initiatives by different non-profit organizations and federations.
Smoking Cessation Market Landscape
The Smoking Cessation treatment market landscape offers tremendous opportunities to pharmaceutical players in the healthcare market to explore and develop novel therapies since there are only a few approved non-nicotinic therapies available commercially. Thus, there is undoubtedly a positive scenario of the market domain in the coming decade. However, the Smoking Cessation market size growth is anticipated to face a few hurdles here and there, says DelveInsight. Strict pricing and reimbursement policies are two of those. At present, many insurance plans cover Champix for a low or USD 0 co-pay. Similarly, The French Health Insurance reimburses nicotine substitutes and Champix. The arrival of the generics is another roadblock in the smooth transition of the Smoking Cessation market size. With the generics of Zyban are already available in the market, and Champix is going to go off-market soon, the market for these branded products is expected to fall in the forecasted period 2021-30. Overall, the market growth is going to traverse steadily in the coming decade if everything goes as planned.
Smoking Cessation Pipeline Therapies
- AXS-05: Axsome Therapeutics
- Cytisinicline: Axsome Therapeutics
- Nadolol (INV102): Chronic Airway Therapeutics
- NFL-101: Smoke Free Therapeutics (NFL Biosciences SAS)
- Liraglutide: Novo Nordisk
Discover more about therapy set to grab substantial Smoking Cessation market trends @ Smoking Cessation Therapeutics Market
Scope of the Smoking Cessation Market Insight Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period- 2022-2032
- Smoking Cessation market companies are working such as Pfizer, GlaxoSmithKline, Axsome Therapeutics, Achieve Life Sciences, among several others are developing therapies for the treatment of Smoking Cessation.
- Smoking Cessation pipeline therapies such as varenicline tartrate, bupropion hydrochloride, EVT 302, Supplement: Probiotic L008-1, Sham Treatment, Acetium Lozenge, and others.
- Smoking Cessation Market Drivers, Barriers, Access, Unmet Needs
Table of Content
1. Key Insights
2. Smoking Cessation Executive Summary
3. Competitive Intelligence Analysis for Smoking Cessation
4. Smoking Cessation: Market Overview at a Glance
5. Smoking Cessation: Disease Background and Overview
6. Patient Journey
7. Smoking Cessation Epidemiology and Patient Population
8. Smoking Cessation Treatment Algorithm, Current Treatment, and Medical Practices
9. Smoking Cessation Unmet Needs
10. Key Endpoints of Smoking Cessation Treatment
11. Smoking Cessation Marketed Products
12. Smoking Cessation Emerging Therapies
13. Smoking Cessation: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Smoking Cessation Market Outlook
16. Access and Reimbursement Overview of Smoking Cessation
17. KOL Views
18. Smoking Cessation Market Drivers
19. Smoking Cessation Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Know which therapy is expected to score the touchdown first @ Smoking Cessation Market Drivers and Barriers
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/